We will be comparing the differences between Magenta Therapeutics Inc. (NASDAQ:MGTA) and Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) as far as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Magenta Therapeutics Inc.	N/A	0.00	57.60M	-4.62	0.00
Madrigal Pharmaceuticals Inc.	N/A	0.00	32.81M	-2.13	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides Magenta Therapeutics Inc. and Madrigal Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Magenta Therapeutics Inc.	0.00%	0%	0%
Madrigal Pharmaceuticals Inc.	0.00%	0%	0%

Liquidity

13.7 and 13.7 are the respective Current Ratio and a Quick Ratio of Magenta Therapeutics Inc. Its rival Madrigal Pharmaceuticals Inc.’s Current and Quick Ratios are 57.5 and 57.5 respectively. Madrigal Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Magenta Therapeutics Inc.

Insider & Institutional Ownership

Roughly 56.5% of Magenta Therapeutics Inc. shares are held by institutional investors while 95.7% of Madrigal Pharmaceuticals Inc. are owned by institutional investors. Insiders held 14.76% of Magenta Therapeutics Inc. shares. Competitively, Madrigal Pharmaceuticals Inc. has 3.2% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Magenta Therapeutics Inc.	48.38%	122.68%	73.25%	8.03%	0%	173.86%
Madrigal Pharmaceuticals Inc.	1.75%	19.8%	20.7%	-42.37%	11.43%	23.03%

For the past year Magenta Therapeutics Inc. was more bullish than Madrigal Pharmaceuticals Inc.

Summary

Madrigal Pharmaceuticals Inc. beats on 3 of the 4 factors Magenta Therapeutics Inc.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.